JP2007051134A - D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 - Google Patents
D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 Download PDFInfo
- Publication number
- JP2007051134A JP2007051134A JP2006196750A JP2006196750A JP2007051134A JP 2007051134 A JP2007051134 A JP 2007051134A JP 2006196750 A JP2006196750 A JP 2006196750A JP 2006196750 A JP2006196750 A JP 2006196750A JP 2007051134 A JP2007051134 A JP 2007051134A
- Authority
- JP
- Japan
- Prior art keywords
- allose
- psicose
- pain
- neuropathic pain
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 88
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 title claims abstract description 74
- 230000000694 effects Effects 0.000 title description 34
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 239000000126 substance Substances 0.000 claims abstract description 16
- 150000000837 D-psicose derivatives Chemical class 0.000 claims abstract description 15
- 150000000715 D-allose derivatives Chemical class 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 208000004983 Phantom Limb Diseases 0.000 claims abstract description 6
- 206010056238 Phantom pain Diseases 0.000 claims abstract description 6
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims abstract description 6
- 206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 6
- 208000001387 Causalgia Diseases 0.000 claims abstract description 5
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims abstract description 5
- 208000007514 Herpes zoster Diseases 0.000 claims abstract description 5
- 208000004550 Postoperative Pain Diseases 0.000 claims abstract description 5
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims abstract description 5
- 206010029240 Neuritis Diseases 0.000 claims abstract description 4
- 230000000116 mitigating effect Effects 0.000 claims abstract description 4
- 208000007117 Oral Ulcer Diseases 0.000 claims abstract description 3
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 3
- 208000007565 gingivitis Diseases 0.000 claims abstract description 3
- 201000001245 periodontitis Diseases 0.000 claims abstract description 3
- 208000003265 stomatitis Diseases 0.000 claims abstract description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 80
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000008034 disappearance Effects 0.000 claims 2
- 230000007246 mechanism Effects 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 description 58
- 230000036407 pain Effects 0.000 description 54
- 239000003814 drug Substances 0.000 description 34
- 235000013305 food Nutrition 0.000 description 22
- 208000000114 Pain Threshold Diseases 0.000 description 19
- 230000037040 pain threshold Effects 0.000 description 19
- 230000000202 analgesic effect Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 229940035676 analgesics Drugs 0.000 description 14
- 239000000730 antalgic agent Substances 0.000 description 14
- 150000008163 sugars Chemical class 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003651 drinking water Substances 0.000 description 11
- 235000020188 drinking water Nutrition 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 235000013373 food additive Nutrition 0.000 description 8
- 239000002778 food additive Substances 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 102100037601 P2X purinoceptor 4 Human genes 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229960005181 morphine Drugs 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 101710189967 P2X purinoceptor 4 Proteins 0.000 description 4
- 230000003063 anti-neuropathic effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 208000001294 Nociceptive Pain Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- -1 nortriptin) Chemical compound 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000001642 activated microglia Anatomy 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001323 aldoses Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001759 blood-nerve barrier Anatomy 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002584 ketoses Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FBXFSONDSA-N Allitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-FBXFSONDSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 150000001365 allose derivatives Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 210000004044 posterior horn cell Anatomy 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 102000027509 sensory receptors Human genes 0.000 description 1
- 108091008691 sensory receptors Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
Abstract
【解決手段】 D−アロース、D−アロース誘導体、D−プシコースおよびD−プシコース誘導体からなる群から選ばれる一以上の物質を有効成分とする、好ましくは0.01〜90重量%含む神経因性疼痛の消失、緩和あるいは軽減組成物。D−アロースおよび/またはD−アロース誘導体、ならびに、D−プシコースおよび/またはD−プシコース誘導体の混合物を1:1〜10:1の割合で含む。三叉神経痛、術後痛、歯周炎、歯肉炎、口内炎、口腔潰瘍、帯状疱疹、帯状疱疹後神経痛、糖尿病性神経炎、カウザルギー、幻肢痛および悪性腫瘍からなる群から選ばれる疾病による神経因性疼痛である。神経因性疼痛を患う患者に、該一以上の物質の一日あたりの摂取量は0.01〜100gであるように与えて神経因性疼痛を消失、緩和あるいは軽減することを特徴とする上記いずれかの組成物を用いる方法。
【選択図】 図1
Description
従来これらの糖の大部分は大量生産ができず入手困難であったため、その生理活性や薬理活性に関する研究はほとんどなされていなかった。最近、香川大学農学部何森らにより酵素を用いた大量生産方法が開発され、その生物活性に関する研究が進んでいる。D−アロースについては白血球を用いたin vitro実験で活性酸素産生抑制作用等が、D−プシコースについては同様の実験で活性酸素消去作用やMCP−1分泌抑制作用などが見出されている(特許文献1)。
治療(改善)とは、神経が傷害された後に薬物を投与することにより、神経因性に発現した疼痛を抑制する効果を指し、異常化した痛覚閾値を正常値付近にまで戻すことにより疼痛を和らげ、あるいは消失させる効果を発揮することを言う。
上記研究に基づき、本発明は、疼痛を緩和・軽減して種々の病態を現わす神経因性疼痛患者のQOLの改善が可能で、それら患者用に適したD−アロースおよび/またはその誘導体および/またはD−プシコースおよび/またはその誘導体をそれぞれ単独あるいはこれらの混合物を含有する組成物、食品、患者用食品、食品素材、患者用食品素材、食品添加物、患者用食品添加物、飲料、患者用飲料、飲料水、薬剤、製剤原料、飼料、疼痛時に使用する飼料を提供することを目的とする。
本発明は、各種の病態を示す神経因性疼痛を緩和・軽減することが可能で、D−アロースおよび/またはその誘導体あるいはD−プシコースおよび/またはその誘導体のそれぞれ単独あるいはこれら両者の混合物を有効成分として含有する組成物、食品、患者用食品、食品素材、患者用食品素材、食品添加物、患者用食品添加物、飲料、患者用飲料、飲料水、患者用飲料水、薬剤、製剤原料、飼料、疼痛時に使用する飼料などの組成物を提供することができる。
また本発明は、D−アロースおよび/またはその誘導体あるいはD−プシコースおよび/またはその誘導体のそれぞれ単独あるいはこれら両者の混合物を有効成分として含有する組成物を用いることを特徴とする神経因性疼痛を緩和・軽減する方法を提供することができる。
ラット神経因性疼痛モデルであるChungモデルにおいて、D−アロースおよびD−プシコースはそれぞれ単独に経口投与した場合に、発現時間が早く、比較的強い鎮痛効果を示した。また、これら希少糖の両者を併用した場合には、相互に鎮痛効果を増強した。
6週齢の雄SDラットを用い、1群を10匹とした。試験物質の抗神経因性疼痛効果を見るために、Chungモデルを作製した。すなわち、腰髄神経のうち片側の第5および第6腰髄神経をできるだけ腰椎に近い部位で完全結紮した。10日間の回復期間の後、手術側の足底部に対してvon Frey testを行い、疼痛閾値を測定した。von Frey testは、それぞれ1週間の休薬期間をおいて3回行った。第1回目はD−アロースの、第2回目はD−プシコースの、第3回目はD−アロースとD−プシコースの混合物の、それぞれの疼痛閾値に対する効果を検討した。
結果は平均値及び標準誤差で表し、平均値の有意差検定は、Dunnett’s
multiple testを用いて行なった。
D−アロースの効果について検討した第1回目の薬物投与前のvon
Frey testでの疼痛閾値は、4.4±0.3gであった。D−アロース1g/kg投与によっては、疼痛閾値は精製水投与群と較べて有意な差は見られなかった。D−アロース3g/kg投与群では投与15分後に、D−アロース6g/kg投与群では、投与15分、30分および60分に、それぞれ精製水投与群と較べて有意な疼痛閾値上昇が見られた(図1)。
神経因性疼痛は、通常は全く痛みを感じない接触や温度変化を痛みと感じたり、通常は痛みと感じない程度の刺激を痛みとして感じるといった異常な状態にあり、その患者のQOLは極めて低い。神経因性疼痛は、何らかの神経損傷により発現すると考えられているが、その発現機序には複数のものがある。そのため、発現する病態も複雑で決定的な治療法は未だ出てきていない。このような状況下では、治療法の種類をなるべく多く開発し、病態ごとに対応することが現在考えられる最良の対応である。そのためには、薬物であればできるだけ性質の異なった多くの種類の薬物を鎮痛薬として開発することが必要となる。
Pain, 26, 61-84, 1986,Pain, 43, 205-218, 1990,Kim, S.H. and Chung, J.M., Pain, 50, 355-363, 1992)。本研究で用いた神経因性疼痛モデルであるChungモデルは、接触刺激により強い疼痛を発現するという特徴を持つモデルで、ヒトの神経痛によく似た疼痛を発現することで知られている(Exp. Brain Res., 113, 200-206, 1997)。これらのモデルにおいては、接触による疼痛の強さを測定するためにvon Frey testが用いられることが多い。von Frey testは、細い金属線で足底部を押して足を引っ込めるかどうかを見る方法である。足を引っ込めたときに足底部を押していた力をそのときの閾値とする。
Claims (6)
- D−アロース、D−アロース誘導体、D−プシコースおよびD−プシコース誘導体からなる群から選ばれる一以上の物質を有効成分とする神経因性疼痛の消失、緩和あるいは軽減組成物。
- D−アロースおよび/またはD−アロース誘導体、ならびに、D−プシコースおよび/またはD−プシコース誘導体の混合物をそれぞれ0.01〜90重量%含む請求項1の神経因性疼痛の消失、緩和あるいは軽減組成物。
- D−アロースおよび/またはD−アロース誘導体、ならびに、D−プシコースおよび/またはD−プシコース誘導体の混合物を1:1〜10:1の割合で含む請求項2の神経因性疼痛の消失、緩和あるいは軽減組成物。
- D−アロース、D−アロース誘導体、D−プシコースおよびD−プシコース誘導体からなる群から選ばれる一以上の物質の一日あたりの摂取量が0.01〜100gである請求項1ないし3のいずれかの神経因性疼痛の消失、緩和あるいは軽減組成物。
- 神経因性疼痛が、三叉神経痛、術後痛、歯周炎、歯肉炎、口内炎、口腔潰瘍、帯状疱疹、帯状疱疹後神経痛、糖尿病性神経炎、カウザルギー、幻肢痛および悪性腫瘍からなる群から選ばれる疾病による神経因性疼痛である請求項1ないし4のいずれかの神経因性疼痛の消失、緩和あるいは軽減組成物。
- 神経因性疼痛を患う患者に、D−アロース、D−アロース誘導体、D−プシコースおよびD−プシコース誘導体からなる群から選ばれる一以上の物質の一日あたりの摂取量が0.01〜100gであるように与えて神経因性疼痛を消失、緩和あるいは軽減することを特徴とする請求項1ないし5に記載のいずれかの組成物を用いる方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006196750A JP5116071B2 (ja) | 2005-07-20 | 2006-07-19 | D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 |
DE602006019432T DE602006019432D1 (de) | 2005-07-20 | 2006-07-20 | Nutzung des antineuropathischen schmerzeffekts von d-allose und d-psicose |
US11/995,974 US8012940B2 (en) | 2005-07-20 | 2006-07-20 | Utilization of anti-neuropathic pain effect of D-allose and D-psicose |
AT06781323T ATE493991T1 (de) | 2005-07-20 | 2006-07-20 | Nutzung des antineuropathischen schmerzeffekts von d-allose und d-psicose |
EP06781323A EP1905442B1 (en) | 2005-07-20 | 2006-07-20 | Utilization of anti-neuropathic pain effect of d-allose and d-psicose |
PCT/JP2006/314363 WO2007010973A1 (ja) | 2005-07-20 | 2006-07-20 | D-アロースおよびd-プシコースの抗神経因性疼痛効果の利用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005209492 | 2005-07-20 | ||
JP2005209492 | 2005-07-20 | ||
JP2006196750A JP5116071B2 (ja) | 2005-07-20 | 2006-07-19 | D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007051134A true JP2007051134A (ja) | 2007-03-01 |
JP5116071B2 JP5116071B2 (ja) | 2013-01-09 |
Family
ID=37668845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006196750A Active JP5116071B2 (ja) | 2005-07-20 | 2006-07-19 | D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8012940B2 (ja) |
EP (1) | EP1905442B1 (ja) |
JP (1) | JP5116071B2 (ja) |
DE (1) | DE602006019432D1 (ja) |
WO (1) | WO2007010973A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4841617B2 (ja) * | 2006-03-03 | 2011-12-21 | 株式会社希少糖生産技術研究所 | 抗線虫用組成物および抗線虫性組成物を用いる線虫制圧法 |
WO2015118699A1 (ja) * | 2014-02-05 | 2015-08-13 | 学校法人自治医科大学 | 満腹感持続剤および満足感を維持する方法 |
KR20170032899A (ko) * | 2014-07-21 | 2017-03-23 | 로께뜨프레르 | 직접 압축에 의한 타정을 위한 당 조성물 |
JP2017522032A (ja) * | 2014-07-21 | 2017-08-10 | ロケット フレールRoquette Freres | 直接圧縮により錠剤化するための糖組成物 |
CN115335061A (zh) * | 2020-03-23 | 2022-11-11 | 国立大学法人香川大学 | 包含d-阿洛糖作为活性成分的用于治疗或预防肾细胞癌的组合物、以及使用其治疗或预防癌症的方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6216493B2 (ja) * | 2011-06-24 | 2017-10-18 | 国立大学法人 香川大学 | 寿命延長剤 |
GB201309077D0 (en) | 2013-03-15 | 2013-07-03 | Tate & Lyle Ingredients | Improved sweetener |
GB201309076D0 (en) | 2013-03-15 | 2013-07-03 | Tate & Lyle Ingredients | Improved sweetener |
GB201309079D0 (en) | 2013-03-15 | 2013-07-03 | Tate & Lyle Ingredients | Improved sweetner |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097820A1 (fr) * | 2002-05-22 | 2003-11-27 | Fushimi Pharmaceutical Co.,Ltd. | Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8904354D0 (sv) | 1989-12-21 | 1989-12-21 | Matti Siren | A pharmaceutical composition |
FR2807043B1 (fr) | 2000-03-28 | 2002-11-22 | Aventis Pharma Sa | Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation |
EP1328236B1 (en) | 2000-09-20 | 2011-04-06 | The General Hospital Corporation | Methods of decreasing or preventing pain using spicamycin derivatives |
US20050074819A1 (en) * | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
JP4724823B2 (ja) | 2004-03-19 | 2011-07-13 | 国立大学法人 香川大学 | 希少糖の神経細胞における保護作用を利用する予防薬、治療薬、特定保健用食品 |
JP4724824B2 (ja) | 2004-03-19 | 2011-07-13 | 国立大学法人 香川大学 | 希少糖のtリンパ球の増殖抑制への使用 |
WO2006093292A1 (ja) | 2005-03-04 | 2006-09-08 | National University Corporation Kagawa University | D-プシコースとd-アロースの複合体結晶性糖質およびその製造方法 |
-
2006
- 2006-07-19 JP JP2006196750A patent/JP5116071B2/ja active Active
- 2006-07-20 WO PCT/JP2006/314363 patent/WO2007010973A1/ja active Application Filing
- 2006-07-20 DE DE602006019432T patent/DE602006019432D1/de active Active
- 2006-07-20 EP EP06781323A patent/EP1905442B1/en active Active
- 2006-07-20 US US11/995,974 patent/US8012940B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097820A1 (fr) * | 2002-05-22 | 2003-11-27 | Fushimi Pharmaceutical Co.,Ltd. | Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4841617B2 (ja) * | 2006-03-03 | 2011-12-21 | 株式会社希少糖生産技術研究所 | 抗線虫用組成物および抗線虫性組成物を用いる線虫制圧法 |
WO2015118699A1 (ja) * | 2014-02-05 | 2015-08-13 | 学校法人自治医科大学 | 満腹感持続剤および満足感を維持する方法 |
JP2015164900A (ja) * | 2014-02-05 | 2015-09-17 | 学校法人自治医科大学 | 満腹感持続剤および満足感を維持する方法 |
KR20170032899A (ko) * | 2014-07-21 | 2017-03-23 | 로께뜨프레르 | 직접 압축에 의한 타정을 위한 당 조성물 |
JP2017522032A (ja) * | 2014-07-21 | 2017-08-10 | ロケット フレールRoquette Freres | 直接圧縮により錠剤化するための糖組成物 |
KR102501024B1 (ko) * | 2014-07-21 | 2023-02-20 | 로께뜨프레르 | 직접 압축에 의한 타정을 위한 당 조성물 |
CN115335061A (zh) * | 2020-03-23 | 2022-11-11 | 国立大学法人香川大学 | 包含d-阿洛糖作为活性成分的用于治疗或预防肾细胞癌的组合物、以及使用其治疗或预防癌症的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1905442B1 (en) | 2011-01-05 |
US20090264374A1 (en) | 2009-10-22 |
WO2007010973A1 (ja) | 2007-01-25 |
US8012940B2 (en) | 2011-09-06 |
EP1905442A1 (en) | 2008-04-02 |
JP5116071B2 (ja) | 2013-01-09 |
EP1905442A4 (en) | 2009-07-29 |
DE602006019432D1 (de) | 2011-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5116071B2 (ja) | D−アロースおよびd−プシコースの抗神経因性疼痛効果の利用 | |
JP2002518456A (ja) | 脳血管の正常状態を支持するための栄養補助食品 | |
US20040101595A1 (en) | Antioxidative compositions | |
WO2008031322A1 (fr) | Application d'un médicament inhibiteur d'acétylcholine estérase à base d'un extrait de leonurus utilisé en tant que cholinomimétique | |
Djaldetti et al. | Effect of cisapride on response fluctuations in Parkinson's disease | |
KR101186898B1 (ko) | 항산화 조성물 | |
EP2138174A1 (en) | Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management | |
KR101899546B1 (ko) | 플로로글루시놀을 유효성분으로 하는 수면 장애 개선, 예방 또는 치료용 조성물, 또는 gaba a 수용체 효능제의 내성 억제 또는 부작용 경감용 조성물 | |
JP2021507887A (ja) | コリンアルホスセラートを有効成分とする神経障害性疼痛(神経因性疼痛)の治療、改善又は予防用の組成物及び方法 | |
KR101793308B1 (ko) | 5-ht3 수용체 길항제인 사인 추출물을 포함하는 구토 또는 설사의 치료용 조성물 | |
KR101671008B1 (ko) | TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 식욕억제용 약학적 조성물 | |
Sicuteri et al. | Fenfluramine headache | |
US9415064B2 (en) | Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate | |
KR102124880B1 (ko) | 데커신 또는 이의 유도체를 포함하는 말초신경병증 예방 또는 치료용 조성물 | |
US6326400B1 (en) | N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement | |
WO2023002979A1 (ja) | 新規化合物およびそれを用いた末梢神経障害の予防又は改善剤 | |
KR101817761B1 (ko) | 부자-유황 복합제제 | |
KR20120055159A (ko) | 감국 추출물을 포함하는 불면 증상의 예방 및 개선용 조성물과 그의 제조방법 | |
CN1180789C (zh) | 一种治疗偏头痛的复方药物 | |
GHOSIAN et al. | Assessment of Hyoscyamus niger seeds alcoholic extract effects on acute and chronic pain in male NMRI rats | |
KR20230024725A (ko) | 으름 추출물을 포함하는 만성통증 완화 또는 치료용 조성물 | |
JP2005263762A (ja) | 神経因性疼痛に対し鎮痛効果を示す新規組成物 | |
KR20230024724A (ko) | 비파 추출물을 포함하는 만성통증 완화 또는 치료용 조성물 | |
KR20220139672A (ko) | 리나릴 아세테이트를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 | |
KR20220160269A (ko) | 갈라민트리에티오디드를 유효성분으로 포함하는 근육질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060928 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090612 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120614 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120926 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121012 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5116071 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151026 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |